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Fatty acidX-linked adrenoleukodystrophy (X-ALD) is an inherited neurodegenerative disorder expressed as four dis-
ease variants characterized by adrenal insufﬁciency and graded damage in the nervous system. X-ALD is
caused by a loss of function of the peroxisomal ABCD1 fatty-acid transporter, resulting in the accumulation
of very long chain fatty acids (VLCFA) in the organs and plasma, which have potentially toxic effects in
CNS and adrenal glands. We have recently shown that treatment with a combination of antioxidants contain-
ing α-tocopherol, N-acetyl-cysteine and α-lipoic acid reversed oxidative damage and energetic failure, to-
gether with the axonal degeneration and locomotor impairment displayed by Abcd1 null mice, the animal
model of X-ALD. This is the ﬁrst direct demonstration that oxidative stress, which is a hallmark not only of
X-ALD, but also of other neurodegenerative processes, such as Alzheimer's disease (AD), Parkinson's disease
(PD) and Huntington's disease (HD), contributes to axonal damage. The purpose of this review is, ﬁrst, to dis-
cuss the molecular and cellular underpinnings of VLCFA-induced oxidative stress, and how it interacts with
energy metabolism and/or inﬂammation to generate a complex syndrome wherein multiple factors are con-
tributing. Particular attention will be paid to the dysregulation of redox homeostasis by the interplay be-
tween peroxisomes and mitochondria. Second, we will extend this analysis to the aforementioned
neurodegenerative diseases with the aim of deﬁning differences as well as the existence of a core pathogenic
mechanism that would justify the exchange of therapeutic opportunities among these pathologies. This arti-
cle is part of a Special Issue entitled: Metabolic functions and biogenesis of peroxisomes in health and disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
X-linked adrenoleukodystrophy (X-ALD: McKusick no. 300100) is
a neurometabolic genetic disorder characterized by progressive de-
myelination in the central nervous system (CNS), axonopathy in the
spinal cord, and adrenal insufﬁciency. The disease is caused by muta-
tions in the ABCD1 (ALD) gene in Xq28, that encodes for the peroxi-
somal ABCD (ALD protein or ALDP) transporter [1], which imports
VLCFA-CoA esters into the peroxisome, where they are degraded bylic functions and biogenesis of
aboratory, Institut d'Investiga-
pitalet de Llobregat, Barcelona,
rights reserved.β-oxidation [2]. X-ALD is the most common monogenic leukodystro-
phy and peroxisomal disorder, occurring in at least 1 out of 17,000
males [3,4].
Four major disease variants have been described: i) a late-onset
and slowly progressing form affecting adult men and women, called
adrenomyeloneuropathy (AMN), as it presents peripheral neuropa-
thy and distal axonopathy in spinal cord, often, but not always, asso-
ciated with axonal or demyelinating peripheral neuropathy; ii) AMN
with cerebral demyelination in adult males that becomes inﬂamma-
tory in many cases; iii) cerebral inﬂammatory demyelination in
boys and adolescent males; iv) and, ﬁnally, peripheral adrenal insuf-
ﬁciency (Addison's disease) in boys, adolescents and adult males
which is not fully penetrant. Patients with this ﬁnal form are at, how-
ever, a 100% risk of developing later cerebral demyelination or AMN.
The cerebral inﬂammatory demyelinating forms of X-ALD that occur
in boys, adolescent and adult males are fatal.
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the peripheral nerves, the brain white matter or the adrenal glands.
The observation that approximately 20% of male patients with adult
AMN develop cAMN [5], suggests the possibility of a pathogenic con-
tinuum of increased severity.
Whatever its location or variant, X-ALD is a disease that affects
axons. In the brain variants demyelination causes severe axon dam-
age and neuronal death, while in AMN there is direct damage to
axons in the spinal cord and in peripheral nerves, with demyelination
being secondary. In this review we will discuss: i) how the abnormal
accumulation of VLCFA may lead to either form of X-ALD by creating a
syndrome of energy metabolism impairment and inﬂammation via
oxidative stress, and ii) whether some of these lessons can be applied
to major neurodegenerative diseases, in order to better understand
the pathogenic interplay of staple disease factors such as oxidative
stress, inﬂammation and energy metabolism disturbance.
2. A word on oxidative stress and damage
Chemical reactions in nervous system are under strict enzyme
control and conform to a tightly regulated metabolic program in
order to minimize unnecessary side reactions. Nevertheless, appar-
ently uncontrolled and potentially deleterious reactions occur, even
under physiological conditions. The term “reactive oxygen species”
(ROS) comprises a variety of molecules and free radicals (chemical
species with one unpaired electron) physiologically generated from
the metabolism of molecular oxygen [6]. ROS include superoxide
anion (O−2), hydrogen peroxide (H2O2), hydroxyl radical (HO•), per-
oxyl radical (RO•2), alkosyl radical (RO•), hydroperoxyl radical
(HO•2), hypochlorous acid (HOCl), hypobromous acid (HOBr), and
singlet oxygen (O2) [6].
ROS are extremely reactive and have damaging effects. Despite the
fact that ROS can be generated at various sites and as a consequence
of various conditions, including ischemia–reperfusion and enzymatic
reactions (e.g. the membrane NADPH oxidase, lipoxygenases,
cyclooxygenases, peroxidases, and other heme proteins, the enzyme
xanthine oxidase, β-oxidation in peroxisomes, and detoxifying reac-
tions in hepatic P-450 microsomes) in healthy cells under physiolog-
ical conditions, most ROS originate in mitochondria [6]. Superoxide
anion, the product of a one-electron reduction of oxygen, is the pre-
cursor of most ROS, and a mediator in oxidative chain reactions. The
character of the radical is not limited to oxygen containing species,
as nitrogen-, chloride- and sulﬁde-containing molecules are also rad-
ical species that could also play signiﬁcant pathophysiological roles.
Globally, in cells of the nervous system the major sites of physiologi-
cal ROS generation are the complex I and III of the mitochondrial elec-
tron transport chain, which contain several redox centers (ﬂavins,
iron–sulfur clusters, and ubisemiquinone) capable of transferring
one electron to oxygen to form a superoxide anion [7].
Since nervous cells continuously produce free radicals, their oxi-
dative stress homeostasis is only guaranteed if an adequate pool of
endogenous cellular antioxidants is present. A large battery of antiox-
idant defenses, both enzymatic and nonenzymatic, have been select-
ed and conserved during evolution [8]. Superoxide dismutase (SOD)
eliminates the superoxide radical converting it to oxygen and H2O2.
There are different forms of this enzyme: a Cu,Zn form in the cytosol
and in the intermembrane mitochondrial compartment, a Mn form in
the mitochondrial matrix, and another form in the extracellular com-
partment. The mitochondrial enzyme is essential for life, its decline
leading to mitochondrial dysfunction, pathology, or neonatal lethali-
ty, depending on the level of depletion; MnSOD overexpression can
protect against pro-apoptotic or pro-ischaemic insults. SOD alone,
however, cannot be considered strictly as an antioxidant because, al-
though it eliminates superoxide radicals, it produces another mole-
cule which could be a ROS source, H2O2. Thus, other enzymes work
in a coordinated manner, eliminating the hydrogen peroxideproduced by SOD and other sources. Two main kinds of enzymes per-
form this task. Catalase decomposes H2O2 at high rates but shows low
afﬁnity for peroxide and is most useful during peaks of H2O2 produc-
tion or accumulation. These peaks must occur in vivo, because acata-
lasemia increases oxidative stress and induces pathologies in humans
[9]. Glutathione peroxidases (GSH-Px), present in selenium- and
nonselenium-dependent forms, are complementary to catalase,
since they decompose H2O2 slowly but with higher afﬁnity. Thus,
they are most useful to decompose the small amounts of peroxide
continuously produced inside cells. Different GSH-Px forms have
been described in the cytosol, mitochondria and cellular membranes,
and they can reduce inorganic or organic peroxides. At least ﬁve
selenium-containing GSH-Px have been identiﬁed, and their activity
can be manipulated by changing dietary selenium levels. These en-
zymes use the reduced form of glutathione (GSH) to decompose per-
oxide. In this process oxidized glutathione (GSSG), which is highly
toxic to cells, is generated. GSSG is then reduced back to GSH by glu-
tathione reductase (GSH-Red), another antioxidant enzyme, which
uses the NADPH generated by the pentose phosphate pathway or by
the NADH–NADPH–transdehydrogenases. Indeed, GSH is a cofactor
of GSH-Px and the major endogenous antioxidant produced by the
cells, participating directly in the neutralization of free radicals and
reactive oxygen compounds, as well as maintaining exogenous anti-
oxidants such as vitamins C and E in their reduced (active) forms.
Glutathione exists in reduced (GSH) and oxidized (GSSG) states,
with GSH being predominant and thus maintaining the cytosol in
strong “reducing” conditions. Another thiol-related redox-active sub-
stance is the protein thioredoxin. Thioredoxin has a redox-active di-
sulﬁde/dithiol at the active site. Its activation by ROS regulates
transcription factors (such as nuclear factor kappaB and AP-1), thus
mounting a defensive response. Accordingly, it is induced by various
oxidative stresses and is translocated to the nucleus. Thioredoxin is
cytoprotective against oxidative stress by scavenging ROS in coopera-
tion with peroxiredoxin/thioredoxin-dependent peroxidase.
Apart from GSH, vitamin C is the next most abundant reduced
non-enzymatic antioxidant inside cells [10]. It is endogenously syn-
thesized in most vertebrates (although not in human beings, fruit
bats or guinea pigs), and it is maintained at levels as high as 1 mM
in some tissues. After reacting with ROS, the oxidized form of ascor-
bate must be reduced by NADPH-, GSH- or NADH-dependent reduc-
tases to regain antioxidant capacity [10].
Tocopherols and carotenoids are the main radical scavenger anti-
oxidants that act in lipophilic environments of cells, a fact that is par-
ticularly relevant for the nervous system. The major scavenger inside
membranes is D-α-tocopherol (vitamin E) [10]. Most membranes are
thought to contain approximately one tocopherol molecule per thou-
sand lipid molecules. Vitamin E acts on lipid peroxyl groups inside
membrane bilayers, reducing them to hydroperoxides, and thus inhi-
biting the propagation of the peroxidative chain reaction. It breaks
the chain reaction of lipid peroxidation but is itself converted to a rad-
ical during the process. Vitamin E also reduces lipid alcoxyl radicals to
lipid alcohols. Oxidized vitamin E can be recycled back to its reduced
form by ascorbate or ubiquinone (coenzyme Q). Other lipophilic anti-
oxidants comprise the carotenoids and ubiquinol. The former quench
singlet oxygen, and interact with other ROS at physiological tissue ox-
ygen partial pressures. Ubiquinol, the reduced form of coenzyme Q, is
also an important antioxidant. It is a hydroquinone that is synthesized
and present in all cellular membranes, and its antioxidant activity is
exhibited through scavenging of lipid radicals and reduction of vita-
min E radical. Regeneration of coenzyme Q is performed by reduc-
tases that use NADPH or NADH as cofactors.
ROS also participate in signal transduction in physiological condi-
tions [11], but when net ROS production surpasses the above-
mentioned antioxidant barriers, a condition of “oxidative stress”
arises in which ROS may cause structural and functional changes in
all cellular constituents including DNA, RNA, lipids and proteins.
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modiﬁcation induced in biological molecules by free radicals if such
change results in function impairment) occurs whenever the ROS
produced by mitochondria avoid detoxiﬁcation, the steady-state
level of molecular oxidative damage depending on the relative rates
of damage accumulation, repair, and degradation. The primary cellu-
lar target of oxidative stress depends upon the cell type, the nature of
the stress imposed, the susceptibility to oxidation of the target mole-
cule, the site of generation, the proximity of ROS to a speciﬁc target,
and the severity of the stress. In this context, protein oxidation de-
mands a special mention because proteins constitute the major
‘working force’ for all forms of biological work. Furthermore, their
exact conformation and pattern of folding are tightly related to their
activity and function. So, the resulting loss of function and structural
integrity of oxidatively modiﬁed proteins can have a wide range of
downstream functional consequences and may be the cause of subse-
quent cellular dysfunction and tissue damage. In this scenario, the
primary change of metal-catalyzed protein oxidation is carbonylation
represented in the carbonyl derivatives glutamic semialdehyde (GSA)
and aminoadipic semialdehyde (AASA) [12,13], which are among the
most speciﬁc markers of protein oxidation. In addition, oxidative
modiﬁcations of proteins may be caused by reactive carbonyl com-
pounds derived from the oxidation of carbohydrates and lipids, lead-
ing to the formation of advanced glycation and lipoxidation end-
products in proteins including malondialdehyde-lysine (MDAL),
carboxylmethyl-lysine (CML), and carboxyethyl-lysine (CEL) [14,15].
The high content of highly peroxidizable polyunsaturated fatty
acids in membranes, the presence of catecholamines prone to oxida-
tion, the elevated oxygen consumption, and the relatively poor ex-
pression of enzymatic antioxidant defenses in the CNS, compared to
other tissues, help explain its high susceptibility to oxidative damage
[7,16]. An often overlooked fact is, however, worth stressing: The un-
equivocal diagnosis of oxidative damage requires both detection of
ROS-mediated structural changes and proof of functional impairment,
for the physiological actions of ROS involve oxidation of molecules,
too [11].
The double-edged role of oxidation is exempliﬁed in nitric oxide
(NO), which is the result of oxidation of L-arginine by nitric oxide
synthases (NOS), which plays a key role in host defense, vascular re-
activity and neurotransmission. However, NO is the source of very
deleterious reactive nitrogen species (RNS) like peroxynitrite. RNS
are produced by highly activated cells of the immune system, includ-
ing astrocytes and microglia, and characteristically lead to the forma-
tion of 3-nitrotyrosine as well as to the oxidation of some amino acid
residues [17]. Glutathione-S-transferase, which uses GSH as a sub-
strate, destroys peroxynitrates [18]. Thus, antioxidant reactions
aimed at increasing GSH also protect the cell from RNS.
3. Oxidative stress and damage in X-ALD patients
Signs of oxidative modiﬁcation have been reported in postmortem
X-ALD brains as well as in skin-derived ﬁbroblasts, plasma, and blood
cells, which are surrogates to study diseases of the CNS in which af-
fected tissues can be accessed only post-mortem. Thus, there is a
very robust increase in nitrotyrosylated proteins, NOS2 and lipid per-
oxidation products within the neuropathological inﬂammatory lesion
of cALD or cAMN, associated with astrocytosis and microgliosis
[19,20]. Manganese superoxide dismutase (MnSOD), a mitochondrial
enzyme that increases in response to oxidative stress, was also upre-
gulated as determined by immunohistochemistry, pointing to mito-
chondrial alterations in the pathological zones [20]. Interestingly,
while oxidation markers were characteristically present in the core
of cerebral and cerebellar white matter lesions, these were also
detected beyond [20]. These data are of relevance because they pro-
vide a picture of early stages in disease progression that are plausibly
more amenable to therapeutic intervention. Recently, we haveconﬁrmed by a functional genomic analysis the existence of a proin-
ﬂammatory reaction in still normal looking white matter of cALD
and cAMN patients [21].
In plasma, Vargas' laboratory has reported increased lipid peroxi-
dation by analysis of TBARS (thiobarbituric acid reactive substances)
in plasma of cALD and AMN patients, and, to a lesser extent, in
asymptomatic carriers of ABCD1 mutations [22]. The antioxidant de-
fense, measured by the capacity to quench peroxidase, inversely mir-
rored these changes as it was reduced in cALD and AMN patients,
while appearing normal in asymptomatic patients. This suggests
that an efﬁcient anti-oxidant defense could impede the disease
development in asymptomatic subjects [22]. There is also increased
oxidative stress in X-ALD ﬁbroblasts [23], and free radical production
in X-ALD lymphoblasts [24]. This implies that oxidative stress is a
generalized phenomenon in different cell types linked to the loss of
function of the ABCD1 transporter/ALD protein and the accumulation
of fatty acids. Moreover, our laboratory has shown by very sensitive
gas chromatography/mass spectrometry (GC/MS) techniques that
the markers MDAL, CEL and CML, GSA and AASA were increased by
two-fold in ﬁbroblasts derived from X-ALD patients [25]. The obser-
vations were extended with analysis of the effects of exogenously-
added C26:0, which caused ROS and oxidative damage in proteins.
It is worth stressing that X-ALD ﬁbroblasts responded more acutely
to C26:0 than did control cells, suggesting impaired anti-oxidant de-
fense consistent with the detected depletion of GSH [25].
4. Early oxidative stress and damage in X-ALD mice
The advantage of a representative mouse model over postmortem
patient materials is the possibility to carry out a longitudinal charac-
terization of the disease process, thus allowing the discrimination of
causative events from epiphenomena. Three mouse models for X-
ALD have been independently generated following a classical strategy
of knocking out the Abcd1 gene, located also in the X chromosome in
the mouse genome [26–28]. None of the mousemutants present cere-
bral demyelination or inﬂammatory signs up to six months of age, in
spite of elevated levels of VLCFA in the nervous tissue, adrenal glands
and other organs [26–28]. However, histological signs of axonopathy
in sciatic nerves are detected at 16 months of age, and the animals
display microglia activation and astrocytosis and axonal swellings
and damage at 20–22 months of age, concomitant with locomotor al-
terations and altered motor nerve conduction velocities [29,30]. Thus,
this mouse model mimics the spinal cord axonopathy present in pa-
tients affected with pure AMN [29], and constitutes a bona ﬁde
model to dissecting physiopathogenetic mechanisms.
Regarding oxidative homeostasis, no evidence of ROS production
or oxidative modiﬁcation was reported in brain, adrenal cortex or
kidney from 3-month-old Abcd1 null mice [20]. However, there
were increases in MnSOD immunostaining in cerebellum, liver, and
adrenal and kidney cortices [20], pointing to an incipient redox alter-
ation, because MnSOD is characteristically activated by oxidative
stress. We thus set out to thoroughly investigate the presence and
time course of oxidative damage in the nervous system, using GC/
MS to quantify oxidation-derived protein modiﬁcations such as the
above explained GSA, AASA, CML, CEL and MDAL. While no increase
in the concentration of markers of oxidative modiﬁcation was ob-
served at 18 days, MDAL was increased at 3.5 months, and GSA,
AASA, CEL and MDAL at 12 months, in a selective manner, as no in-
creased levels were observed in cerebral cortex or liver. Thus, oxida-
tive stress occurs well before disease onset in X-ALD mice, increases
with time, and is target-organ speciﬁc. Lipid peroxidation as evi-
denced by MDAL arises as the earliest quantitative disease marker
[25]. Of note, the same quantitative markers were increased by two-
fold in ﬁbroblasts derived from X-ALD patients.
In an ensuing study we discovered by redox proteomics [31] that
the oxidative modiﬁcation of proteins speciﬁcally affects ﬁve key
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phosphoglycerate kinase, pyruvate kinase, dihydrolipoamide dehy-
drogenase and mitochondrial aconitase. Moreover, we conﬁrmed
that the oxidative alteration led to damage because we discovered,
by metabolomic measurements of substrates and/or products, that
these enzymes were inactivated, and we showed depletion of NADH
and ATP [32]. These data conﬁrm the notion hinted at in our previous
studies: there is a metabolic derangement in spinal cords of Abcd1
null mice prior to development of neurological symptoms, thus lend-
ing support to the idea that energy failure may be a pathogenic factor,
at least in adult forms of X-ALD (see below).
5. What causes oxidative stress in X-ALD?
The studies from our laboratory in human X-ALD ﬁbroblasts
showing that hexacosanoic acid in excess directly increases steady-
state ROS production, depletes GSH, and decreases mitochondria
membrane potential serve to argue that VLCFA is the agent initiating
oxidative stress in X-ALD [25]. This is not an effect restricted to hex-
acosanoic acid, as an excess of the monounsaturated C26:1 fatty
acid, also a VLCFA whose levels are increased in X-ALD, generates
ROS in human ﬁbroblasts [33].
By what mechanisms does VLCFA generate free radicals? As dis-
cussed above, mitochondria, peroxisomes, endoplasmic reticulum,
microsomes, nucleus and plasma membrane oxidases are potential
sources of ROS. In X-ALD, neither the exact source of free radicals
nor the molecular mechanism of production has yet been elucidated;
this information is essential to the development of tailored therapeu-
tic strategies. In light of recent ﬁndings, several scenarios are dis-
cussed below. We highlight mitochondria as the most important
ROS-producing organelle as a result of electron-transfer reactions,
and also as relevant to the subject of this review, peroxisomes,
which carry β-oxidation of fatty acids. Peroxisomes are an important
source of total cellular H2O2 production [34]. They contain a number
of H2O2-generating enzymes including glycolate oxidase, d-amino
acid oxidase, urate oxidase, l-α-hydroxyacid oxidase, and fatty acyl-
CoA oxidase. Peroxisomal catalase utilizes H2O2 produced by these
oxidases to oxidize fatty acids in “peroxidative” reactions [35].
5.1. The peroxisome–mitochondria connection
There is growing evidence that both organelles exhibit a closer in-
terrelationship than previously noted. This cross-talk includes: i)
metabolic cooperation, for instance, the mitochondria can oxidize
hexacosanoic CoA produced in peroxisomes by a CoA synthase [36],
indicating that VLCFA derivatives can be shuttled from peroxisomes
to mitochondria for full oxidation; ii) vesicular trafﬁcking through
Vps35 [37]; iii) a shared biogenesis through the activation of peroxi-
some proliferator activated receptors/peroxisome proliferator
gamma coactivator-1 (PPAR/PGC-1) transcription factors [38] and a
key component of the ﬁssion machinery, the Drp1 protein [39,40],
and iv) a redox connection. Thus, Koepke et al. [41] have observed
that inhibition of peroxisomal catalase not only leads to an H2O2 ele-
vation, but that it also causes mitochondrial dysfunction, as the trea-
ted cells show decreased inner mitochondrial membrane potential
concomitant with enhanced mitochondrial ROS production. These
ﬁndings have recently been reinforced in an elegant study showing
that generating ROS inside peroxisomes disturbs the mitochondrial
redox balance, which may lead to excessive mitochondrial fragmen-
tation and ROS production [42]. The close relationship between both
organelles is ﬁnally supported by morphological evidence of mito-
chondria impairment in peroxisomal Pex5 knockout mutant mice
[43] and Zellweger syndrome patients, who lack functional peroxi-
somes [44]. Likewise, Abcd1 and Abcd2 knockout mice present abnor-
mal, swollen mitochondria ﬁlled with lipidic inclusions and
condensation of cristae in neurons of spinal cord [45], suggesting arole for the mitochondria in the physiopathology of peroxisomal
disorders.
An excess of VLCFA may also affect mitochondria directly. As
noted, mitochondria are major sources of ROS in the CNS. They con-
tain redox carriers that can transfer single electrons to oxygen, thus
generating the superoxide radical. Enzymes of the tricarboxylic acid
cycle such as aconitase and ketoglutarate dehydrogenase, as well as
the electron transport chain (complexes I, II, and II) and monoamine
oxidases are among the mitochondrial redox carriers also generating
superoxide radicals. As noted above, mitochondria also contain en-
zymes able to detoxify ROS. Superoxide is transformed into hydrogen
peroxide by superoxide dismutases (SOD), enzymes which work in
conjunction with catalases and glutathione peroxidases to remove
H2O2 from mitochondria. It is worth noting that SOD1 and SOD2
have reduced expression in spinal cords of Abcd1 null mice [25].
Interestingly, in isolated mitochondria, long-chain fatty acids such
as the branched chain phytanic acid stimulate ROS production by in-
hibition of the forward electron transport in the respiratory chain
[46,47]. Similar experiments performed with the VLCFA C22:0,
C24:0 and C26:0 showed that mitochondria exposed to C22:0 and
C24:0 fatty acids, but not C26:0, suffered uncoupling and inhibition
of the respiratory chain. By contrast, while mitochondrial membrane
potential was markedly decreased, in particular by C22:0, in cultures
of oligodendrocytes, neurons and astrocytes, none of the VLCFA used
stimulated ROS production from isolated mitochondria. Instead, the
highly toxic effects of C26:0 were attributed to dysfunction of calcium
homeostasis [48]. This is a canonical calcium- and mitochondria-
mediated apoptosis. A caveat of this study is the time frame of cellular
demise. In the CNS, X-ALD is characterized by slow degeneration and
ultimately selective cellular death over years, even in the severe
childhood demyelinating variant, rather than by acute cell death
within hours, suggesting that other pathogenic mechanisms play
roles in the detrimental effects of VLCFA in a real physiopathological
setting.
In addition, it should be noted that experiments were performed
in whole cells or isolated mitochondria from rat brain or liver with in-
tact Abcd1 function. Mitochondrial function, and its response to
VLCFA load, should be addressed in mitochondria from Abcd1
mouse models or human cells. In addition, studies of VLCFA cytotox-
icity have mostly been performed using free fatty acids. These proce-
dures might bring a limitation in, as the largest pool of fatty acids in
the cells is not found free, but as components of complex lipids. In
particular, VLCFA are constitutive of phospholipids and other lipidic
species, such as gangliosides, phosphatidylcholine, and cholesterol
ester fractions of brain myelin, as well as in the proteolipid fraction
[49–51].
Finally, the recently uncovered loss of function of key mitochon-
drial enzymes of the Krebs cycle, aconitase and α-ketoglutarate dehy-
drogenase in X-ALD [32], supports a functional impairment of
mitochondria. Note that these enzymes are targets of oxidative dam-
age in spinal cords of Abcd1 null mice. That is, a vicious cycle arises
whereby the mitochondrial enzymes are at the same time targets of
free radicals, and ROS contributors when they are impaired.
5.2. Secondary peroxisomal dysfunction
ABCD1 loss results not only in accumulation of VLCFA outside per-
oxisomes, but also in another defective peroxisomal function, the
synthesis of plasmalogens. These vinyl ether phospholipids with
reported antioxidant activities are decreased in brains from X-ALD
patients [52], and lower levels of plasmalogens have been reported
to exacerbate pathology in the Abcd1 null mouse [53]. However, it is
not clear how ABCD1 disruption may reduce plasmalogen contents.
On the one hand, peroxisome biosynthesis appears to require acyl-
CoA generated by the peroxisomal β-oxidation pathway [54], sug-
gesting that a lower import of the VLCFA-CoAs, the substrate of β-
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CoA availability. But, on the other hand, mice with a severe defect in
peroxisomal β-oxidation, the MFP2 knockout mice, have normal
levels of plasmalogens in brain [55], indicating that plasmalogen syn-
thesis can proceed in the absence of β-oxidation. Whatever the rea-
son underlying the decrease, the reduced contents of plasmalogens,
together with the lower contents of the antioxidant enzymes SOD1
and SOD2 [25], may certainly render the nervous tissue more vulner-
able to free radical attacks. Accordingly, loss of Abcd1 gene function
sensitizes ﬁbroblasts to death upon GSH depletion in the culture me-
dium. Overall, the data indicate that Abcd1 dysfunction hampers oxi-
dative stress homeostasis by increasing ROS while decreasing
antioxidant defenses. This hypothesis is reinforced by the fact that se-
lective peroxisome ablation in oligodendrocytes leads to cerebral ax-
onal degeneration and inﬂammatory demyelination in brain,
suggesting that the contribution of peroxisomal-related additional
metabolic derangements is necessary to ignite the inﬂammatory re-
sponse in mouse brain, and perhaps in X-ALD patients [56,57].
5.3. Cellular membranes
NADPH oxidase is a plasma membrane-bound complex that gen-
erates superoxide by transferring electrons from NADPH inside the
cell across the membrane, and coupling these to molecular oxygen.
Superoxide can spontaneously form peroxide. In the brain, NADPH
oxidase is found in astrocytes and microglia [58,59]. Fatty acids
have been described as NAPDH oxidase activators in neutrophils
[60] and epithelial cells [61]. Indeed NADPH oxidase has been
shown to generate free radicals in ﬁbroblasts from X-ALD patients,
which do accumulate VLCFA, concomitant to an increase in the pro-
tein contents of its membrane anchored catalytic subunit p91PHOX,
while mRNA levels remained normal, as do the protein contents of
the cytoplasmic NADPH subunits p47PHOX or p67PHOX [24]. The au-
thors speculate that VLCFA incorporation into plasma membranes
may contribute to destabilization and changes in membrane proper-
ties as reported [62–64] altering membrane microdomains (lipid
rafts) [60] which would result in cell signaling disturbances, thus in-
terfering with the turnover of NADPU p91PHOX [24].
Another potential source of ROS is the 5-lipoxygenase enzyme (5-
LOX), which belongs to the arachidonic acid metabolizing family of
inﬂammatory enzymes. This has been found elevated in cALD brain,
even in intact areas, and its levels are increased depending on exoge-
nous hexacosanoic acid levels [65]. 5-LOX converts products of ara-
chidonic acid metabolism into leukotriene LT4. Leukotrienes are
signaling molecules playing roles as chemoattractants or inducing
cell death. Because leukotrienes modify cysteine residues of pro-
teins/peptides, including glutathione (GSH), they are implicated in
oxidative stress and subsequent inﬂammation [66]. Taken together,
the available evidence discussed so far indicates that there are two
sources of oxidative damage in X-ALD: i) inﬂammation, which entails
the production of vast amounts of RNS and ROS from glial cells, NOS2,
NADPH oxidase and 5-LOX being the primary sources, respectively;
and ii) the chained dysfunction of peroxisomes and mitochondria
leading to a severe rupture of redox homeostasis.
6. Inﬂammation and oxidative stress are intertwined
The observation that C26:0-accumulating lymphoblasts from X-
ALD patients release pro-inﬂammatory cytokines along with ROS
[24] points to a joint regulation of inﬂammation and oxidative stress
by VLCFA. This is hardly surprising, since it is well established that in-
ﬂammatory processes are tightly controlled by oxidative stress
through the presence of redox sensors in key regulators of inﬂamma-
tory responses (reviewed in [67]). One is the transcription factor
NFκB, which has redox-reactive cysteine residues, the same as the I-
κB kinase necessary for NFκB activation. These residues aresusceptible to modiﬁcation by reactive carbonyl compounds (e.g.
hydroxynonenal, HNE), prostaglandins, NO and ROS. As advanced
above, nitrosylation suppresses the translocation and DNA-binding
of NFκB [68], while H2O2 activates these parameters in synergy with
cytokines [69]. The duration of these interactions is exquisitely
attuned to the redox potential established by the major redox-
controlling systems, GSH/GSSG or thioredoxin [70–73].
Another molecule characteristically regulated by oxidative stress
is Nrf2, a transcription factor that coordinates the synthesis of antiox-
idant systems, reducing systems, and Nrf2 itself, via the antioxidant
response element (ARE) present in the 5′ regulatory region of target
genes [74]. Nrf2 is activated when oxidative stress modiﬁes thiol
groups in Keap1, thereby releasing the transcription factor. Neurons
lacking Nrf2 are more susceptible to excitotoxic damage [75], indicat-
ing a key protective role of the factor under oxidative stress.
That two transcription factors with opposing roles can be regulat-
ed by oxidative stress unravels the intricate regulation of redox ho-
meostasis. In this context, it is plausible to propose that high levels
of ROS released by neurons, oligodendrocytes or other glial cells
may activate an initially protective inﬂammatory response in glial
cells via NFκB. Persistence or increased dose of the primary stimuli
(e.g. VLCFA or cellular debris), or defective counteractive mechanisms
(e.g. anti-inﬂammatory cytokines, or Nrf2-dependent protection)
may push glia inﬂammation across an irreversible threshold, leading
to aberrant activation as in cALD. The discovery of what drives the in-
ﬂammatory reaction in AMN beyond homeostatic control to cause
cAMN will obviously have important therapeutic implications.
7. Oxidative stress causes energy failure
Energy homeostasis and antioxidant defense cannot be considered
independently as both are regulated by the ratios of redox-active co-
factors NADH/NAD+, NADPH/NADP+ and GSH/GSSG [76]. NADH/
NAD is linked to the synthesis of ATP via glycolysis and oxidative
phosphorylation. NADH is produced by the TCA in mitochondria and
is used as a substrate for complex I of the respiratory chain. The cellu-
lar ratio of NADPH/NADP+ in turn depends on the consumption of
NADPH in antioxidative and biosynthetic enzyme reactions, and on
the regeneration of NADPH by NADPH/regenerating enzymes. The
GSH/GSSG ratio is determined by the NADPH consuming enzyme glu-
tathione reductase, while glycolysis and the pentose phosphate cycle
are predominantly responsible for the cytosolic reduction of NAD+
and NADP+, respectively.
In spinal cords from Abcd1 null mice we found diminished levels
of NADH and ATP [32], most likely due to the aforementioned mal-
function of TCA cycle and glycolitic enzymes resulting, in turn, from
the early, pre-symptomatic oxidative damage to key proteins, thus
conﬁrming an overall bioenergetic failure (Fig. 1). Indeed, it has
been suggested that oxidative modiﬁcation of key mitochondrial
TCA enzymes such as pyruvate and α-ketoglutarate dehydrogenases
and aconitase may be an important pathophysiological factor in vari-
ous neurodegenerative diseases [77–79]. GSH was diminished as
expected under conditions prone to oxidative damage.
Oxidative phosphorylation (OXPHOS) in mitochondria is the main
route to producing ATP. However, there was no impairment of
OXPHOS activities in whole spinal cords [32], in agreement with pre-
vious results in isolated mitochondria from muscle of Abcd1 null and
control mice [80]. These results suggest that metabolic failure is most
likely due to impairment in glycolysis, although we cannot rule out
the possibility that OXPHOS impairment in selected brain cells (e.g.
neurons, see below) goes unnoticed in measurements in whole tissue.
Spinal cords contain a mixture of gray and white matter. Neurons
represent around 10% of the total amount of cells, whereas glia ac-
counts for rest, with astrocytes being the most abundant cell type. En-
ergy is mainly produced bymitochondria in neurons and by glycolysis
in astrocytes in culture conditions [81]. Astrocytes export lactate
Fig. 1. ABCD1 loss-of-function leads to axonal degeneration via oxidative stress. The schematic presents a model of X-ALD pathogenesis based on evidence obtained in the animal
model of AMN. VLCFA accumulation due to mutations in ABCD1 would cause a direct oxidative damage to enzymes implicated in glycolysis and TCA. This would cause a decrease in
pyruvate and hence of Acetyl-CoA delivery to the mitochondria, thereby impairing TCA and ETC and reducing NADH+ and ATP contents. The mitochondria dysfunction would wors-
en oxidative stress, manifested as a decrease in the ratios of GSH/GSSG and NADPH(H+)/NADP+ redox couples. The chained bioenergetic failure would elicit axonal degeneration.
GSH: reduced glutathione; GSSG: oxidized glutathione; TCA: tricarboxylic acid cycle; ETC: electron transfer chain; PPP: pyrophosphates; OMM: outer mitochondrial membrane.
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chondria and support axonal function under conditions of energy
deprivation [82]. Thus, a reduction of ATP in astrocytes would be
owing to defective glycolysis, while in neurons it could be due to a re-
duction of NADH generation in mitochondria caused by the damage
to KGDHC and aconitase and/or to some other unidentiﬁed enzymes.
In a different neuropathological scenario, according to ﬁndings in a
mouse model of Alzheimer's disease (AD), glycolysis induction
could be a mechanism to compensate for mitochondria dysfunction,
in metabolic reprogramming [83]. This reprogramming would not
be efﬁcient in Abcd1 null spinal cords, as ALDO A, PFK1 and PKM2
are oxidized and their activity might be altered.
Energy deﬁciency has fatal consequences for axons because of
their unusual size and high metabolic demands. It has been shown
that reduced ATP production in affected neurons reduces their capac-
ity to respond to the high energy demands of axonal transport and
synaptic input. This may lead to axonal degeneration in our particular
scenario, and also to neuronal demise in the most common neurode-
generative diseases [84].
8. Cascade of events leading to X-ALD: a model of
disease pathogenesis
In Fig. 2 we present possible scenarios of cALD and AMN patho-
genesis. We posit that inﬂammation and energy failure are the
major players in X-ALD. In c-ALD, both inﬂammation and energy fail-
ure would overlap to cause oligodendrocyte and axonal death. The ro-
bust inﬂammatory reaction involves the release of toxic ROS and RNS
as well deleterious cytokines like TNFα. The striking recovery of cALD
patients observed after allogeneic hematopoietic stem celltransplantation, which gives rise to healthy microglia in the brain
[85], does demonstrate a key role of microglia in the cerebral forms
of X-ALD, possibly through abnormal cytokine and chemokine release
of ABCD1-deﬁcient microglial cells. An interesting twist on the regu-
lation of inﬂammation in X-ALD is that VLCFA and other fatty acids
(FA) may be signaling molecules connecting the immune system
and the metabolism since pathways regulating metabolic and im-
mune functions overlap [86]. This may allow nutrients such as fatty
acids to act through pathogen-sensing systems such as Toll-like re-
ceptors (TLRs), giving rise to metabolic or nutritionally induced re-
sponses [87]. It is tempting to speculate that the fatty acids
accumulated due to Abcd1 inactivation could activate TLR signaling,
leading to NFκB-induced pro-inﬂammatory response in X-ALD, with
the subsequent activation of pro-inﬂammatory cytokines.
By contrast, AMN has been traditionally considered a non-
inﬂammatory condition. However, recent observations from our lab-
oratory point to the existence of an early, pre-symptomatic and pro-
inﬂammatory reaction in spinal cords of Abcd1 null mice, the model
of adult AMN [21]. Inﬂammation hence does occur in supposedly
non-inﬂammatory X-ALD phenotypes, although its protective or del-
eterious role remains unknown. Until this is clariﬁed, axon degenera-
tion can be attributed primarily to the energy failure, perhaps
originating in the wrapping oligodendrocytes, in view of the ﬁnding
that peroxisomes in oligodendrocytes play key roles in the mainte-
nance of axons and myelin throughout adult life [56].
A note on the non-speciﬁc vs. receptor-mediated actions of VLCFA.
The enrichment of membranes with VLCFA is the earliest biochemical
abnormality in brain tissues from X-ALD patients [51], suggesting that
this is the trigger for the ensuing pathogenic cascade. As noted, VLCFA
are usual constituents of complex lipids such as gangliosides,
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Fig. 2. X-ALD as a metabolic/inﬂammatory syndrome. The ﬂowchart describes a model of X-ALD pathogenesis encompassing speciﬁc factors causing X-ALD variants. The key idea is
that X-ALD is pathogenic continuum of increased severity where multiple noxious factors accumulate in a highly interactive manner to cause cALD or AMN. VLCFA-elicited oxidative
stress would be the ﬁrst hit, followed by inﬂammation leading to cALD and perhaps to AMN.
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that are characteristically abundant in myelin sheets. Biophysical ap-
proaches have revealed that VLCFA disrupts cellular membranes in a
long-lasting manner, because the desorption rate of these molecules
is slower than that of short chain fatty acids [63]. The incorporation
of VLCFA to complex lipids might destabilize cell membranes result-
ing in cell signaling disturbances [62–64]. VLCFA may thus cause
membrane destabilization of myelin leading to demyelination. Axonal
degeneration can also be a consequence, because the integrity of the
cellular membrane is a prerequisite for myelin–axonal interaction.
However, at present, it is not known whether and how membrane
disruption by VLCFA causes peroxisomal and mitochondrial dysfunc-
tion, oxidative stress, energy failure or inﬂammation, or acts as an ad-
ditional etiopathogenic factor. The very early events in VLCFA-
inﬂicted damage and X-ALD pathogenesis are particularly obscure.
In addition, research from our laboratories and other groups has
hitherto provided a general picture of X-ALD pathogenesis with
scant detail about cell compartmentalization. Above, we pointed out
possible distributions of inﬂammatory or metabolic pathways
among astrocytes and oligodendrocytes, but understanding of cell-
speciﬁc actions of VLCFA, and the pathological engagements of neural
cells, remain pending issues in X-ALD research that need to be
addressed.
9. A hope for a treatment: antioxidants against
axonal degeneration
Above, we outlined current knowledge on pathways leading to X-
ALD (Figs. 1, 2). As noted, genetically-modiﬁed stem cells have
yielded excellent results in cALD [85]. However, there is as yet notherapy to halt the slow progression of axonopathy in AMN, or to pre-
vent the conversion of AMN into the deadly cAMN.
The very upstream position of oxidative stress in the pathogenic
cascades brings this process to the center stage of AMN therapeu-
tics. It is not trivial, however, how to tackle oxidative stress, since
it encompasses a network of multiple signaling pathways. Ideally,
reliable interactome maps should be used to select strategic net-
work nodes leading to reduced ROS production, increased anti-
oxidant protection, and improved mitochondrial function, leading
to reversal of energetic failure. In the absence of cell-speciﬁc inter-
actomes to model drug actions in AMN, a rougher but valid ap-
proach is to combine antioxidant therapies to target several spots
with synergistic effects. In this line, we have recently undertaken a
“proof-of-concept” study on the causative role of oxidative stress
in axonopathy by testing a combination of anti-oxidants in Abcd1
null mice [88].
The cocktail of antioxidants contained: i) α-tocopherol, as it can
inhibit the propagation phase of the peroxidative process by neutral-
izing the lipid-derived radicals [89]; ii) N-acetyl-cysteine, as it can re-
generate reduced glutathione and scavenge several types of ROS
including OH, H2O2, peroxyl radicals and nitrogen-centered free rad-
icals [90]; and iii) α-lipoic acid, which can regenerate GSH from its
oxidized counterpart, ascorbate from dehydroascorbate, and α-
tocopherol from tocopherol radicals, thus enhancing the effects of
the other two compounds [91]. In addition, α-lipoic acid and its re-
duced form, dihydrolipoic acid, may use their chemical properties as
a redox couple to alter protein conformations by forming mixed sul-
ﬁdes, thus protecting proteins from oxidation. Further, since α-
lipoic acid is an essential cofactor of PDHC and KGDHC, it could pro-
tect and increase the enzymatic activity of KGDHC [92], which suffers
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about an increase in NADH and ATP production.
The three antioxidants were initially tested in X-ALD ﬁbroblasts,
where we observed a complete scavenging of VLCFA-dependent
ROS generation when the drugs were used individually [88]. Impor-
tantly, the anti-oxidants displayed synergistic actions, which allowed
using smaller doses of each oxidant in the combination than when
tested individually. Use of several drugs with synergistic effects acting
on unrelated targets may thus permit a considerable reduction in the
dose of each individual compound, increasing selectivity and reduc-
ing adverse events. In addition, the combined anti-oxidant therapy
is aimed at reproducing the multistep, combined response that is ob-
served in vivo leading to recovery after an oxidative challenge [93].
Indeed, combinations of antioxidants have shown beneﬁcial effects
in pathologies associated with increased oxidative stress in mice
[94] and in mitochondriopathies in human patients [95,96].
The antioxidants were administered for 6 months to Abcd1 null
mice between 12 and 18 months of age, that is, when oxidative dam-
age is already taking place and histological and behavioral damage
are on the verge of becoming evident. The results were spectacular,
as the cocktail halted the histopathological signs of axonal degenera-
tion and the onset of locomotor deﬁcits [88]. Signs of oxidative dam-
age to proteins were also abrogated, indicating that the antioxidants
had truly engaged their targets. Indeed, oxidative damage to the
ﬁve proteins differentially oxidized was erased. Metabolic failure
reﬂected by the levels of ATP and ratios of NAD+/NADH was cor-
rected, and the levels of pyruvate kinase and its enzymatic activity
were restored, together with cellular contents of GSH [32]. Experi-
ments were repeated in a double mutant lacking both Abcd1 and
Abcd2 genes (Abcd1/abcd2 null), which develops an earlier and
more severe axonal degeneration phenotype, thus being a more con-
venient model to assay therapeutic approaches [30]. Abcd2 and Abcd1
genes share overlapping functions regarding import of hexacosanoic
and C26:1 fatty acids [97,98], and remarkably, loss of Abcd2 causes
oxidative damage in adrenal glands [99], while the loss of both trans-
porters worsens oxidative damage and VLCFA accumulation [30]. The
double mutant Abcd1/abcd2 null mice were treated after disease
onset, at 12 months of age, during six months. The antioxidant treat-
ment halted and reversed immunohistochemical signs of axonal de-
generation and locomotor disability [88].
To our knowledge, this is the ﬁrst demonstration that antioxidant
therapy prevents or rescues axonal degeneration, and the results
paved the way for a clinical trial in AMN patients that is now in
progress.
Other combinations of antioxidants are most likely possible, in-
cluding other compounds that target mitochondria, stimulate anti-
oxidant defense and mitochondrion biogenesis at the level of tran-
scription of relevant genes, e.g. via Nrf2/ARE, or increase ATP by
mitochondria-independent sources. Clearly, more research is war-
ranted to identify sources of ROS within the cell, and the exact mech-
anism of ROS production, in order to choose the best suited
antioxidants from a growing panoply of compounds able to cross
the blood–brain barrier. Because many antioxidants target mitochon-
dria, it is of paramount importance to ascertain or to rule out the con-
tribution of this organelle to ROS production in X-ALD. And within the
mitochondria, it is important to identify the molecular source of ROS;
i.e. whether the respiratory chain, TCA cycle enzymes and monoami-
nooxidases are relevant ROS sources.
In recent years, great attention has been focused on CoQ10, which
participates in the electron transfer chain. CoQ10 may have, however,
two major limitations as a therapy. First, the functioning of CoQ10 is
dependent entirely on the functioning of the electron transfer chain
which facilitates the redox cycling of the enzyme from ubiquinone
(oxidized form) to ubiquinol (reduced form). This requirement be-
comes critical when oxidatively damaged mitochondria contain dam-
aged electron transfer chain and thus cannot recycle CoQ10appropriately. Second, there is evidence indicating that CoQ10 is un-
able to cross the blood–brain barrier [100,101]. An alternative is the
CoQ10 derivative MitoQ (Antipodean Pharmaceuticals Inc), a
triphenylphosphonium-linked ubiquinone derivative [102]. MitoQ
concentrates highly in the mitochondria because of the large mito-
chondrial membrane potential (Δψm) [103], and is also an effective
antioxidant in the absence of a functioning electron transfer chain
[104,105].
10. Other neurodegenerative diseases as metabolic/inﬂammatory
syndromes caused by oxidative damage
Chronic impairment of bioenergetics and mitochondria metabo-
lism, together with oxidative stress, is a common noxa underlying
age-related, multifactorial neurodegenerative diseases, such as PD,
HD, and AD, to cite a few [16,106–111]. It has been postulated that
oxidative stress in mitochondria can reduce the activities of various
proteins due to oxidative modiﬁcations [77–79,112,113]. Both
mtDNA and protein modiﬁcations have been described as resulting
in a metabolic failure characterized by an increase in NAD+/NADH
ratio (i.e., a decrease in cellular reducing potential), which is a power-
ful regulator of glycolysis, TCA cycle and oxidative phosphorylation
[114], and also in reduced levels of ATP [84,115]. Diminished levels
of ATP have been described in AD and PDmouse models [116,117], al-
though the ratios of NAD/NADH have not been measured in most
prominent neurodegenerative diseases. Most likely linked to the
intertwined oxidative stress and metabolic derangement, such disor-
ders also display early axonal pathologies including abnormal accu-
mulation of proteins and organelles, and disrupted axonal transport,
which is responsible for a substantial part of the debilitating symp-
toms that patients endure [118], see Fig. 3. Thus, therapeutic strate-
gies that are of beneﬁt for the above-mentioned diseases may
deserve testing on X-ALD and vice versa.
10.1. Alzheimer's disease
AD is the most common type of dementia, accounting for an esti-
mated 60–80% of cases. Currently, over 30 million people worldwide
have AD, and with the current steady increase in life-expectancy,
the number of people with AD is forecast to increase to 1 out of 85
people by 2050. Memory loss is the most prevalent and early symp-
tom, often accompanied by apathy and depression. Histological hall-
marks in the brain are plaques of amyloid β (Aβ), and tangles of
hyperphosphorylated tau. Axonal transport defects have been de-
scribed as an early pathological feature in a variety of animal models
[119,120]. Current therapies are limited to drugs that attenuate dis-
ease symptomatology without addressing the causes of the disease.
It is widely considered that Aβ and tau hyperphosphorylation,
which may be causally related, are culprits in the disease, with in-
ﬂammation, oxidative stress and cerebrovascular factors acting as
amplifying elements. However, there has been a failure of over twen-
ty clinical trials aimed at testing drugs against alleged causes of the
disease. Failed drugs include anti-amyloid therapies like the γ-
secretase inhibitor semagacestat and the γ-secretase modulator tar-
enﬂurbil, non-steroidal anti-inﬂammatory drugs (NSAIDs), estrogen,
valproate, the insulin-sensitizers rosiglitazone and pioglitazone, the
cholesterol-reducing drug simvastatin, the antioxidants omega 3/
docosahexaenoic acid (DHA), Gingko biloba, curcumin, and vitamin
E (clinicaltrials.gov). While careful appraisal of each trial reveals on
occasion lack of sound animal data, or evidence that the drug engaged
its target in the brain, the prevailing view is that treatments were
tested too late, when damage is perhaps irreversible. The recognition
that AD progresses in a clinically silent manner over years –perhaps
two decades– before clinical symptoms are manifested is arguably
the most important recent breakthrough in AD [121,122]. This vision
implies that treatments will have to strictly match the onset and
Fig. 3. Oxidative-stress mediated energetic failure may be at the core of multifactorial
neurodegenerative diseases. The schematic illustrates the idea that both common and
distinct factors lead to adrenoleukodystrophy (X-ALD), Alzheimer's disease (AD), Par-
kinson's disease (PD) and Huntington's disease (HD). Distinct factors are: i) the genetic
factors launching the diseases (on top), and the ii) highly speciﬁc anatomical locations
plausibly reﬂecting a mitochondrial and metabolic heterogeneity throughout the brain.
Yet undetermined environmental, epigenetic, genetic and stochastic factors probably
further shape the selective cellular response to noxious agents. Whatever the origins,
all diseases converge on a condition of increased ROS and energy failure with de-
creased ATP, contributing to axonal damage. This complex scenario calls for: i) complex
treatments including antioxidant cocktails already validated in animal models, as well
as disease-speciﬁc therapies; and ii) systems biology approaches to advance in the un-
derstanding of pathogenic mechanisms.
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tion emerges as a key strategic factor in AD therapeutics. The problem
arises that the chronological appearance and interplay of pathogenic
cascades during pre-clinical stages are not known. The recent guide-
lines issued by the National Institute for Aging (NIA) and the Alzhei-
mer Association (AA) in the USA provide a valuable framework forTable 1
Targets of oxidative damage in adrenoleukodystrophy (X-ALD), Alzheimer's disease (AD), H
in two of the diseases are shown.
Short name Fun
Pyruvate kinase isozymes M1/M2 KPYM Gly
Phosphoglycerate kinase 1 PGK1 Gly
Fructose-biphosphate aldolase A ALDOA Gly
Glyceraldehyde-3-phosphate dehydrogenase G3P, GAPDH Gly
Alpha-enolase ENOA Gly
Lactate dehydrogenase LDH Gly
Aconitase hydratase, mitochondrial Aconitase Kre
Dihydrolipoyl dehydrogenase DLDH Kre
Creatine kinase CK Ene
Outer mitochondrial membrane protein porin 1 VDAC Ion
Superoxide dismutase 1 SOD1 Ant
Parkinson disease protein 7 DJ-1 Ant
Peroxiredoxin 2 NKEF-B Ant
Tubulin beta-2A chain TBB2A Cyt
Glial ﬁbrillary acidic protein GFAP Cyt
Carbonic anhydrase 2 CAH2, CAII CO2
αB-crystallin Chaexploring pre-clinical stages [122]. Abnormal brain deposition of Aβ
detected with PET or measurements in CSF, appears to be the earliest
pathological hallmark, followed by neurodegeneration and, later, a
very subtle cognitive decline before entering the clinical categories
of early AD (e.g. Subjective Clinical Complaint (SCI) and Mild Cogni-
tive Impairment (MCI)) [122]. Where in this picture oxidative stress
lies, and how it interacts with Aβ tau or inﬂammation, are outstand-
ing questions in AD.
The presence of oxidative stress and oxidative modiﬁcations in AD
has been overwhelmingly recognized for years, and it has been the
topic of a wealth of studies and reviews [111]. In brief, oxidative mod-
iﬁcations have been detected in postmortem samples from AD pa-
tients affecting DNA [123], along with proteins implicated in
glycolysis and energy metabolism, mitochondrial electron transport
chain and oxidative phosphorylation, structural proteins, chaperones,
stress proteins, and ubiquitin-proteasome system components (see
Table 1) [111], although loss-of-function analysis of oxidized proteins
in AD is for the most part pending. The fact that dozens of proteins
have been reported oxidized in AD, but only ﬁve in X-ALD [32], may
have several explanations. One is the differing stages in disease pro-
gression of the samples used: most of the postmortem samples of
AD were obtained from patients, that is, from late disease, while the
analysis in X-ALD was performed at pre-symptomatic stages in
Abcd1 null mice. Note also that different species were used in the an-
alyses. Another explanation is that there may be a disease-speciﬁc ox-
idative damage that primarily affects energy metabolism in X-ALD,
while in AD it is more widespread; however, ATP synthase, the en-
zyme that catalyzes the synthesis of ATP from ATP and inorganic
phosphate, is consistently found oxidized in AD [124–126], but was
not detected with redox proteomics in X-ALD mice, pointing to fur-
ther unclear differences in the compartmentalization of pathogenic
pathways between AD and X-ALD.
Mitochondrial dysfunction and morphological alterations are also
hallmarks of AD [127,128]. Several antioxidant drugs targeting mito-
chondria are under investigation for the treatment of AD [129]. CoQ10
has been shown to be protective in transgenic models of AD
[130,131], but we saw above that the problem of crossing the
blood–brain barrier impedes the use of this drug to treat brain dis-
eases [100,101]. N-acetyl-cysteine, acetyl-L-carnitine (ALCAR), R-α-
lipoic, polyphenols and tert-butylhydroquinone (TBHQ), alone or in
combination, are protective in cellular and transgenic models of AD,
and in aged animals [132,133]. It has to be stressed that experimental
paradigms in animals are usually preventive, since drugs are adminis-
tered before age- or AD-related damage occurs. Thus, these anti-
oxidant agents hold promise provided that they are administered pre-
ventively to AD patients. Of note, in pilot studies with twelve ADuntington's disease (HD) and Parkinson's disease (PD). Proteins found oxidized at least
ction X-ALD AD HD PD
colysis X X
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colysis X X X X
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cysteine, vitamin E and α-lipoic has been reported [134,135]. Larger
trials are clearly necessary.
The interaction of oxidative stress and inﬂammation in AD is not
well understood. The existence of multiple inﬂammatory mediators
has been widely documented in animal models and in body ﬂuids
and postmortem brains from AD patients [136]. The collected data
have propelled a view in which very toxic byproducts of microglia ac-
tivation, namely free radicals, are a major cause of AD as in the cere-
bral forms of X-ALD. However, there are major caveats attaching to
this conclusion (reviewed in [137]). There is a need for better cellular
and animal models recapitulating inﬂammation in aged brains, par-
ticularly in the preclinical stages, before any immunomodulatory
therapy is designed for AD. This situation mirrors the one existing in
X-ALD, where an animal model of inﬂammatory demyelination as it
occurs in the child variants of disease is still lacking. However, as de-
scribed in Section 8, our recent studies have unraveled the existence
of a pre-symptomatic pro-inﬂammatory cascade in brains from
cALD and cAMN patients, which is reproduced by the mouse model
[21]. At present, the pathological role of this phenomenon is not
clear. A key question is if a basal inﬂammatory reaction may facilitate
the outburst of a lethal demyelinating inﬂammation, particularly in
adults. Conveniently manipulated, the mouse model may be of help
to answer these questions.
By contrast, a large body of evidence in cells and animal models
supports the idea that Aβ and oxidative stress are highly interactive.
Aβ binds to mitochondrial membranes and interferes with the normal
electron ﬂow through the respiratory chain; this results in defective
mitochondrial energy metabolism and increased ROS production
[138–140], reviewed in [141]. Conversely, oxidative stress drives Aβ
production and impairs Aβ clearance in vitro and in vivo [142–145].
Of note, there is an active γ secretase in mitochondria [146], reinfor-
cing the view that Aβ production is closely linked to mitochondrial
activity. Interestingly, a recently elaborated interactome of ApoE has
revealed possible actions of the lipoprotein at the mitochondria
[147], suggesting that ApoE4 may increase the risk of AD by altering
mitochondrial functions.
All in all, these data suggest that abnormal Aβ accumulation and
oxidative stress may be synchronous in AD progression. Since
20–40% of healthy individuals have plaques in the brain after the
age of 65 [121], and projections from PET-based measurements of
Aβ plaque load suggest that the abnormal deposition may start up
to 20 years before the dementia onset [148], it may be reasoned
that oxidative stress is one of the earliest events in AD. Indeed, ATP
synthase was found oxidized and its activity reduced in asymptomat-
ic cases with AD pathology in Braak II stage [149]. Hypometabolism, a
plausible marker of mitochondrial dysfunction as revealed by PET
measurement of ﬂuorodeoxyglucose (FDG), is a very sensitive pre-
symptomatic marker of AD-related neurodegeneration [150]. In AD-
mice, lipid peroxidation and mitochondrial alterations precede Aβ
plaque and tau deposition [151,152]. This evidence supports a scenar-
io in which the interplay between oxidative stress and Aβ oligomers/
ﬁbrils, the initial culprits of AD and upstream triggers of tau patholo-
gy, may further exacerbate Aβ and tau aggregation.
While more research is clearly necessary to characterize oxidative
stress in AD, it appears reasonable that Aβ and oxidative stress, or mi-
tochondrial damage, be therapeutically targeted in unison at pre-
symptomatic stages. Anti-amyloid therapy, e.g. immunotherapy or
Notch-sparing γ secretases, should be combined with a cocktail of an-
tioxidants as in X-ALD. Candidates include antioxidants supported by
the latest animal data (e.g. N-acetyl-cysteine and α-lipoic acid) and
those failing in clinical trials (e.g. vitamin E), under the assumption
that these treatments may not have worked because they were ad-
ministered alone or too late. Finally, measurements in CSF of isopros-
tane, currently the most reliable marker of oxidative stress in ﬂuids
[153], may help to yield further insight into the temporal relationshipbetween Aβ and oxidative stress, and to guide antioxidant therapies
in AD.
10.2. Parkinson's disease
PD is the second most common neurodegenerative disease, affect-
ing over ten million people worldwide. Although PD is most common
in people over 60, many people are diagnosed in their 40s and youn-
ger. PD is characterized by a marked loss of midbrain dopaminergic
neurons localized in the substantia nigra pars compacta. This leads to
progressive rigidity, bradykinesia and tremors. Abnormal aggrega-
tions of α-synuclein (i.e. Lewy bodies) are considered a major patho-
genic factor in the disease, and indeed the most recent animal models
encompass transgenic over-expression or viral delivery of α-
synuclein. Autosomal dominant factors involved in early-onset famil-
ial PD include mutations in the SNCA (α-synuclein), and LRRK2 (leu-
cine-rich repeat kinase 2) genes. Autosomal recessive factors include
mutations in the PARK2 (parkin), PINK1 (PTEN induced putative ki-
nase 1), PARK7 (DJ1), and ATP13A2 (ATPase type 13A2) genes.
Gene wide genomic associations (GWAS) have revealed that SCNA
and LRRK2, among other genes, confer susceptibility to late-onset,
sporadic PD [154].
Models of PD, both sporadic and caused by 1-methyl-4-phenyl-
pyridinium (MPP+) proceed through a “dying back” pattern of neuro-
nal degeneration characterized by early loss of synaptic terminals and
axonopathy, with impairment of fast axonal transport [155]. Numer-
ous studies support the idea that oxidative stress and mitochondrial
dysfunction underlie the development of neuropathology, and there
are excellent reviews on the topic [111,156,157]. Herein we will pin-
point key distinctive facts pertaining to antioxidant treatment in the
disease:
i) Mitochondrial dysfunction appears as an early, upstream if not
causative factor in PD pathogenesis, as judged by the role of
Parkinsonism-linked genes, which maintain mitochondrial in-
tegrity by regulating diverse aspects of mitochondrial function,
including membrane potential, calcium homeostasis, cristae
structure, respiratory activity, mtDNA integrity, and autophagy-
dependent clearance of dysfunctional mitochondria. DJ1 appears
to protect mitochondria against oxidative stress caused by sus-
tained entrance of Ca2+ via L-type channels [158]. Loss of PINK1
causes defective oxidative phosphorylation, production of ROS
and a decrease in mitochondrial content [117,159]. Parkin, a mol-
ecule associated with the outer mitochondrial membrane, is an E3
ligase that targets proteins for degradation in the proteasome or
lysosome [160]. Evidence indicates that parkin may be crucial
for autophagy-dependent clearance of dysfunctional mitochon-
dria [161]. LRRK2 interact with human peroxiredoxin 3, a mito-
chondrial member of the antioxidant family of thioredoxin
peroxidases, and mutations of LRKK2 promote peroxidase dys-
function, dysregulation of mitochondrial function and oxidative
stress [162]. Finally,α-synuclein, although predominantly cytosol-
ic, is detected in mitochondria where it inhibits complex I, and re-
duces ATP synthesis and membrane potential [163]. α-Synuclein
also inhibits mitochondrial fusion, and this effect is rescued by
parkin, DJ1 and PINK1 [164,165], further supporting the role of
these proteins in regulating mitochondrial dynamics. Damage to
mitochondria has been shown to perturb transport of mitochon-
dria through axons [166].
ii) Complex I deﬁciency and glutathione depletion have been found
in the substantia nigra of sporadic and pre-symptomatic PD pa-
tients [167].
iii) Numerous studies have described oxidative modiﬁcations in
PD and in animal models (reviewed in [111]). There is oxida-
tive modiﬁcation selective to mitochondria-associated
metabolic proteins (LDH, enolasa and CA II anhydrase),
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sing the human A30P α-synuclein mutation [168], see Table 1.
In patient brains, in addition to oxidative modiﬁcation and
functional impairment of complex I [169], there are two re-
markable ﬁndings. One is that proteins that confer causality
or susceptibility to familial or sporadic PD are targets of oxida-
tive stress. This is the case of α-synuclein [170], parkin [171],
and DJ1 [172]. A vicious circle may exist whereby dysfunction
of these proteins causes mitochondrial damage and a ROS in-
crease, which damages PD-related proteins further. The second
remarkable ﬁnding is that oxidative modiﬁcations have been
detected not only in the substantia nigra [170], but also in the
cerebral cortex and the amygdala [170,173], at pre-clinical
pre-motor stages of PD (stages II and III in Braak classiﬁcation).
This reinforces the emerging view that PD, like AD, develops
for many years without marked symptoms and that, aside
from the midbrain, the disease affects other brain areas not as-
sociated with Lewy bodies [173–175].
iv) A recent study has implicated down-regulation of two micro-
RNAs, miR-34b and miR-34c, in several brain areas with vari-
able neuropathological involvement at clinical (motor) stages
(Braak stages IV and V) and pre-motor stages (stages I–III) of
the disease. According to additional data, these microRNAs
may be related to mitochondrial function and dynamics, as
well as redox regulation, via DJ1 and parkin [176].
v) Auto-oxidation of dopamine is an important source of intracel-
lular ROS production [177]. The direct product of such auto-
oxidation reactions is the superoxide radical, which may
contribute to the anatomically-speciﬁc degeneration of
dopaminergic neurons in PD.
Restitution of dopamine or dopaminergic activity is the only avail-
able therapy for PD. In view of the aforementioned evidence, and in
the absence of disease-modifying therapies targeted to
Parkinsonism-linked proteins, antioxidant therapies aimed at restor-
ing mitochondrial function and the reduced glutathione, or ROS scav-
engers, remain an option for combination with dopamine analogs.
Indeed, intravenous N-acetyl-cysteine, intranasal glutathione, MitQ,
and the PPAR gamma and Nrf2/ARE activator pioglitazone are being
tested in PD patients at phase I or II (clinicaltrials.gov). A phase IV
has been completed with levodope plus rasagiline, a monoaminooxi-
dase B inhibitor with antioxidant properties, but the results have not
been disclosed yet (clinicaltrials.gov). However, a recent phase III trial
with CoQ10/vitamin E was terminated with the statement that “The
investigational drug is unlikely to demonstrate efﬁcacy over placebo
for this indication” (clinicaltrials.gov). There are two, not incompati-
ble explanations for this failure. One, only more complex agent com-
binations addressing in unison dopamine depletion and several
targets of mitochondrial dysfunction, as well as mitochondria biogen-
esis, will show therapeutic beneﬁts. Two, patients may have been
treated too late; that is, disease-modifying interventions should be
moved to the pre-motor stages of PD. This will require pre-clinical
biomarkers, which are not currently available. In this regard, the re-
cent detection of α-synuclein oligomers in the CSF of PD patients of-
fers hope that the misfolded protein may become a clinical and pre-
clinical marker for PD, as Aβ is for AD [178].
10.3. Huntington's disease
HD is an autosomal dominantly inherited neurodegenerative dis-
ease caused by the expansion of CAG trinucleotide repeats in the hun-
tingtin gene. This gives rise to an elongated polyglutamine sequence
(polyQ) at the N-terminal of the huntingtin protein. The disease starts
when the number of glutamines expands beyond 40, and it is charac-
terized by atrophy of the striatum, intraneuronal huntingtin aggre-
gates, reactive gliosis and, as clinical symptoms, involuntarymovements (chorea), psychiatric disturbances or dementia, and
death after 15–20 years of progression. While the function of normal
huntingtin is not known, polyQ-huntingtin disrupts many cellular
processes: autophagy, energy metabolism, gene transcription,
clathrin-dependent endocytosis, intraneuronal trafﬁcking, postsyn-
aptic signaling and axonal transport [179]. We list below key evi-
dence in support of the view that oxidative stress, mitochondrial
dysfunction and impaired energy metabolism contribute to HD
(reviewed in [180]):
i) PolyQ-huntingtin causes ROS production [181], and there are
mitochondrial defects in HD patients [182]. Indeed, polyQ-
huntingtin interacts with mitochondrial proteins, binding to
the mitochondrial ﬁssion GTPase dynamin-related protein-1
(DRP1) in mice and humans with HD, which, in turn, stimu-
lates its enzymatic activity leading to impairment of mitochon-
drial ﬁssion–fusion balance, mitochondria fragmentation and
neuronal injury [128,183]. In addition, mutant huntingtin re-
presses the expression of PPARγ, coactivator 1 α (PGC-1α), a
transcriptional coactivator that regulates several metabolic
processes, including mitochondrial biogenesis and respiration
[180]. Accordingly, PGC1-α knockouts exhibit impaired mito-
chondrial function, hyperkinetic movement and striatal degen-
eration, as seen in HD [191].
ii) Complex II activity is decreased in the HD brain, and complex II
inhibition with 3-nitropropionic acid induces striatal degener-
ation and movement disorders in rodents and primates [184],
that is, it induces a clinical phenotype very reminiscent of
that in HD.
iii) Redox proteomics identiﬁed seven proteins in HD brains in-
volved in glucose metabolism and mitochondrial energy path-
ways affected by oxidative modiﬁcations see Table 1 [185].
Interestingly, oxidation also affected the activity of enzymes
involved in the metabolism of pyridoxal 5-phosphate (PLP),
the active form of vitamin B6 [185]. PLP acts as a coenzyme
in all transamination reactions and some decarboxylation and
deamination reactions, including the conversion of L-DOPA
into dopamine and glutamate into GABA. Thus, synthesis of do-
pamine and GABA may be impaired, and glutamate accumu-
lates abnormally in HD. Also, there is reduction of antioxidant
systems in brains from HD patients [186].
These data argue in favor of antioxidant therapies speciﬁcally tar-
geting mitochondria. CoQ10 [187], L-carnitine [188], and the Nrf2/ARE
activators triterpenoids [189] have shown protective effects in animal
models of HD. There is currently a phase III trial with CoQ10 and a
phase II with L-creatine (clinicatrials.gov). There is no combination
of antioxidants being currently tested, unfortunately. Finally, the im-
portance of early treatment applies to HD as well. The fact that the
disease can be diagnosed by predictive genetic testing provides a
window of opportunity for intervention aimed at preventing or
delaying disease onset. Biomarkers are therefore needed to monitor
treatment efﬁcacy. Clinical, cognitive, neuroimaging, and biochemical
biomarkers are thus being investigated for their potential in pre-
clinical use for patients with Huntington's disease [190].
11. Concluding remarks
Although the ﬁrst hits in the most prevalent neurodegenerative
conditions and X-ALD are of different etiology and target different
cell types, oxidative stress and associated bioenergetic failure involv-
ing mitochondria dysfunction, together with axonal damage, is a
common bottleneck that justiﬁes the undertaking of similar thera-
peutic strategies. Identifying the molecular mechanisms of ROS gen-
eration and mitochondrial demise in each speciﬁc disease is
necessary to assist in making the best choice among neuroprotective
approaches. Regarding antioxidant treatment, strategies should
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sound animal data supporting the efﬁcacy of multiple-drug combina-
tions, thereby facilitating clearance by government agencies. Disease-
speciﬁc modifying therapies should be combined with anti-oxidant
therapies, the latter containing agents targeting membranes, mito-
chondria function and biogenesis as well as ROS scavengers. Optimal
combinations and doses have to be empirically determined. Because a
wealth of evidence indicates that oxidative stress is a primary patho-
genic factor in neurodegeneration, it is of utmost importance that
drugs be tested as early as possible in the disease progression,
which requires validation of surrogate disease biomarkers. In X-ALD,
longitudinal assessment of oxidative lesions in blood cells, together
with clinical symptoms, will serve to monitor efﬁcacy in an ongoing
clinical trial testing a cocktail of antioxidants in AMN patients. In
AD, the recently reported success of a preclinical trial with donepezil
in cognitively normal subjects paves the way for preclinical trials.
However, in PD and HD, biomarkers are still needed to enroll asymp-
tomatic individuals and/or to assess disease progression. The other
strategic route should lead to further knowledge concerning on the
underpinnings of oxidative stress in inﬂammation and neurodegen-
eration. An outstanding question points to disease speciﬁc pathways,
organelles, cells and brain areas implicated. Despite the many com-
mon themes shared by the diseases, we still do not know why for ex-
ample, complex I or complex II dysfunction leads, respectively, to PD
or HD, at least in experimental models. Nor do we know exactly how
VLCFA, Aβ, or mutant α-synuclein or huntingtin cause mitochondrial
damage, and why the resulting pathologies are vastly different. This
intriguing fact may plausibly be due to a yet unexamined mitochon-
drial and metabolic heterogeneity throughout the brain, which deter-
mines a region-speciﬁc vulnerability to noxious agents. The devil is in
the details when tailoring effective disease-targeted therapies.
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